Tissue factor pathway inhibitor for cardiovascular disorders

Expert Opinion on Emerging Drugs

Volumn 5, Issue 1, 2000, Pages 73-87

  Kaiser, Brigitte ^a   Hoppensteadt, Debra A ^b   Fareed, Jawed ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiovascular disorders; interactions with heparin and low molecular weight heparins; tissue factor; tissue factor pathway inhibitor (TFPI)

Indexed keywords

'TAP'; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ABCIXIMAB; ANTISTASIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING INHIBITOR; BX 807834; EPTIFIBATIDE; FONDAPARINUX; HIRUDIN DERIVATIVE; N ACETYL 4 (AMINOIMINOMETHYL)PHENYLALANYL 2 CYCLOHEXYLGLYCYL 3 (1 METHYLPYRIDINIUM 3 YL) ALANYLLEUCYLPROLINAMIDE; N [1 (2 AMINOIMINOMETHYL 4 THIENYLMETHYL) 2 OXO 3 PYRROLIDINYL] 7 METHOXY N METHYL 2 NAPHTHALENESULFONAMIDE; NAP 5; PROCOAGULANT; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SERINE PROTEINASE INHIBITOR; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; YAGIN; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID;

ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEX FORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; REVIEW; SEPTIC SHOCK; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 0033995531     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.1.73     Document Type: Article

References (86)

1. BROZE GJ, JR.: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag. Fibrinol. (1995) 6(Suppl. 1):S7-S13.
2. BROZE GJ, JR.: Tissue factor pathway inhibitor and the revised theory of coagulation. Ann. Rev. Med. (1995) 46:103-112.
3. MANN KG, KALAFATIS M: The coagulation explosion. Cerebrovasc. Dis. (1995) 5:93-97.
4. CAMERER E, KOLSTØ AB, PRYDZ H: Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb. Res. (1996) 81(1):1-41.
5. BROZE GJ, JR., GIRARD TJ, NOVOTNY WF: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry (1990) 29(33):7539-7546.
6. BROZE GJ, JR.: Tissue factor pathway inhibitor. Thromb. Haemost. (1995) 74(1):90-93.
7. GIRARD TJ, WARREN LA, NOVOTNY WFet al.: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 338(6215):518-520.
8. GIRARD TJ, MCCOURT D, NOVOTNY WG: Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2. Biochem. J. (1990) 270(3):621-625.
9. BROZE GJ, JR., WARREN LA, NOVOTNY et al.: The lipoprotein-associated coagulation inhibitor that inhibits the Factor VII-tissue factor complex also inhibits Factor Xa: insights into its possible mechanism of action. Blood (1988) 71(2):335-343.
10. HUANG ZF, WUN TC, BROZE GJ, JR.: Kinetics of Factor Xa inhibition by tissue factor pathway inhibitor. J. Biol. Chem. (1993) 286(36):26950-26955.
11. LINDHOUT T, FRANSSEN J, WILLEMS G: Kinetics of the inhibition of tissue factor-Factor VIIa by tissue factor pathway inhibitor. Thromb. Haemost. (1995) 74(3):910-915.
12. RAPAPORT SI: Inhibition of Factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a Factor Xa-dependent inhibitory mechanism. Blood (1989) 73(2):359-365.
13. RAPAPORT SI: The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb. Haemost. (1991) 66(1):6-15.
14. YONEDA T, KOMOOKA H, UMEYAMA H: A computer modeling study of the interaction between tissue factor pathway inhibitor and blood coagulation Factor Xa. J. Protein Chem. (1997) 16(6):597-605.
15. BAUGH RJ, BROZE GJ, JR., KRISHNASWAMY S: Regulation of extrinsic pathway Factor Xa formation by tissue factor pathway inhibitor. J. Biol. Chem. (1998) 273(8):4378-4386.
16. PETERSEN LC, BJØRN SE, OLSEN OH et al.: Inhibitory properties of separate recombinant Kunitz-type-protease inhibitor domains from tissue-factor-pathway inhibitor. Eur. J. Biochem. (1996) 235(1-2):310-316.
17. LINDHOUT T, WILLEMS G, BLEZER R, HEMKER HC: Kinetics of the inhibition of human Factor Xa by full-length and truncated recombinant tissue factor pathwayinhibitor. Biochem. J.(1994) 297(Pt 1):131-136.
18. VALENTIN S, REUTLINGSPERGER CP, NORDFANG O, LINDHOUT T: Inhibition of Factor Xa activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive Factor VIIa. Thromb. Haemost. (1995) 74(6):1478-1485.
19. PETERSEN LC, VALENTIN S, HEDNER U: Regulationofthe extrinsic pathway system in health and disease: the role of Factor VIIa and tissue factor pathway inhibitor. Thromb. Res. (1995) 79(1):1-47.
20. VALENTIN S, NORDFANG O, BREGENGÅRD C, WILDGOOSE P: Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coag. Fibrinol. (1993) 4(5):713-720.
21. HOLST J, LINDBLAD B, BERGQVIST D et al.: Antithrom-botic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model. Haemostasis (1993) 23(Suppl. 1):112-117.
22. IINO M, FOSTER DC, KISIEL W: Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler. Thromb. Vasc. Biol. (1998) 18(1):40-46.
23. PETERSEN LC, SPRECHER CA, FOSTER DC et al.: Inhibitory propertiesofanovel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry (1996) 35(1):266-272.
24. NOVOTNY WF, GIRARD TJ, MILETICH JP, BROZE GJ, JR.: Purification and characterization of lipoprotein associated coagulation inhibitor from human plasma. J. Biol. Chem. (1989) 264(31):18832-18837.
25. BROZE GJ, JR., LANGE GW, DUFFIN KL, MACPHAIL L: Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coag. Fibrinol. (1994) 5(4):551-559.
26. NOVOTNY WF, GIRARD TG, MILETICH JP, BROZE GJ, JR.: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood (1988) 72(6):2020-2025.
27. PALMIER MO, HALL LJ, REISCH CM et al.: Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb. Haemost. (1992) 68(1):33-36.
28. BREGENGAARD C, NORDFANG O, ØSTERGAARD P et al.: Pharmacokinetics of full-length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb. Haemost. (1993) 70(3):454-457.
29. ELSAYED YA, NAKAGAWA K, KAMIKUBO YIet al.: Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am. J. Clin. Pathol. (1996) 106(5):574-583.
30. KAMIKUBO Y, HAMURO T, MATSUDA J et al.: Antithrom-botic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravas-cular coagulation in rats: concerted effect with antithrombin. Thromb. Haemost. (1996) 76(4):621-626.
31. KAMIKUBO Y, HAMURO T, MATSUDA J et al.: The clearanceof proteoglycan-associated human recombi-nant tissue factor pathway inhibitor (h-rTFPI) in rabbits:acomplex formationofh-rTFPIwithFactorXa promotes a clearance rate of h-rTFPI. Thromb. Res. (1996) 83(2):161-173.
32. NARITA M, BU G, OLINS GM et al.: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J. Biol. Chem. (1995) 270(42):24800-24804.
33. KAISER B, HOPPENSTEADT DA, FAREED J: Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. Exp. Opin. Invest. Drugs (1998) 7(7):1121-1137.
34. MANN KG, VAN'T VEER C, CAWTHERN K, BUTENAS S: The role of the tissue factor pathway in initiation of coagulation. Blood Coag. Fibrinol. (1998) 9(Suppl. 1):S3-S7.
35. HOPPENSTEADT DA: Tissue factor pathway inhibitoras a modulator of post surgical thrombogenesis. Experi mental and clinical studies. Thesis for the degree of Doctor of Philosophy, University of London, UK (1996).
36. TAUBMAN MB, FALLON JT, SCHECTER AD et al.: Tissue factor in the pathogenesis of atherosclerosis. Thromb. Haemost. (1997) 78(1):200-204.
37. ØSTERUD B: Tissue factor: a complex biological role. Thromb. Haemost. (1997) 78(1):755-758.
38. SATO Y, ASADA Y, MARUTSUK AK et al.: Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/Factor VIIa complex. Thromb. Haemost. (1997) 78(3):1138-1141.
39. KAMIKUBOY, NAKAHARA Y,TAKEMOTO Set al.: Human recombinant tissue factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. (1997) 407(1):116-120.
40. HAMURO T, KAMIKUBO Y, NAKAHARA Y, MIYAMOTO S, FUNATSU A: Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett. (1998) 421(3):197-202.
41. JANG Y, GUZMAN LA, LINCOFF AM et al.: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral arteryinjury model. Circulation (1995) 92(10):3041-3050.
42. OLTRONA L, SPEIDEL CM, RECCHIA D et al.: Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation (1997) 96(2):646-652.
43. ST PIERRE J, YANG LY, TAMIRISA K et al.: Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler. Thromb. Vasc. Biol. (1999) 19(9):2263-2268.
44. ASADA Y, HARA S, TSUNEYOSHI A et al.: Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb. Haemost. (1998) 80(3):506-511.
45. HAN X, GIRARD TJ, BAUM P, ABENDSCHEIN DR, BROZE GJ, JR.: Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler. Thromb. Vasc. Biol. (1999) 19(10):2563-2567.
46. YUTANI C, IMAKITA M, ISHIBASHI-UEDA H et al.: Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol. Int. (1999) 49(4):273-290.
47. FERRARIO M, MERLINI PA, LUCREZIOTTI S et al.: Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction. Int. J. Cardiol. (1999) 68(Suppl. 1):S63-S71.
48. ASADA Y, MARUTSUKA K, HATAKEYAMA K et al.: The role of tissue factor in the pathogenesis of thrombosis and atherosclerosis. J. Atheroscler. Thromb. (1998) 4(3):135-139.
49. FALCIANI M, GORI AM, FEDI S et al.: Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb. Haemost. (1998) 79(3):495-499.
50. SOEJIMA H, OGAWA H, YASUE H et al.: Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation (1999) 99(22):2908-2913.
51. KAMIKURA Y, WADA H, YAMADA A et al.: Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am. J. Hematol. (1997) 55(4):183-187.
52. FREEBURN JC, WALLACE JM, STRAIN JJ et al.: Monocyte tissue factor-like activity in post myocardial infarction patients. Br. J. Haematol. (1998) 102(2):605-608.
53. SAITO Y, WADA H, YAMAMURO M et al.: Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am. J. Hematol. (1999) 61(4):238-242.
54. ABUMIYA T, YAMAGUCHI T, TERASAKI T et al.: Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb. Haemost (1995) 74 (4):1050-1054.
55. DREW AF, DAVENPORT P, APOSTOLOPOULOS J, TIPPING PG: Tissue factor pathway inhibitor expression in atherosclerosis. Lab. Invest. (1997) 77(4):291-298.
56. KAIKITA K, TAKEYA M, OGAWA Hetal.: Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J. Pathol. (1999) 188(2):180-188.
57. CAPLICE NM, MUESKE CS, KLEPPE LS, SIMARI RD: Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation (1998) 98(11):1051-1057.
58. PETIT L, LESNIK P, DACHET C, MOREAU M, CHAPMAN MJ: Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages. Relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler Thromb. Vasc. Biol. (1999) 19(2):309-315.
59. ARIENS RA, ALBERIO G, MOIA M, MANNUCCI PM: Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb. Haemost. (1999) 81(2):203-207.
60. KLEESIEK K, SCHMIDT M, GÖTTING C etal.: The 536C-T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb. Haemost. (1999) 82(1):1-5.
61. SHIMURA M, WADA H, WAKITA Y et al.: Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Hematol. (1997) 55(4):169-174.
62. TAKAHASHIH, SATO N, SHIBATA A: Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb. Res. (1995) 80(4):339-348.
63. YAMAMURO M, WADA H, KUMEDA K et al.: Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul. Fibrinolysis (1998) 9(6):491-497.
64. SHIMURA M, WADA H, NAKASAKI T et al.: Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am. J. Hematol. (1999) 60(2):94-98.
65. VELASCO F, LOPEZ-PEDRERA C, BORRELL M, FONTCU-BERTA J, TORRES A: Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation. Blood Coag. Fibrinol. (1997) 8(1):70-72.
66. MATSUO T, KOIDE M, KARIO K, SUZUKI S, MATSUO M: Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis (1997) 27(4):163-167.
67. YORIOKA N, TANIGUCHI Y, YAMASHITA K et al.: Tissue factor and tissue factor pathway inhibitor in hemodialysis patients. Int. J. Artif. Organs (1998) 21(11):699-701.
68. LUZZATTO G, BERTOLI M; CELLA G et al.: Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb. Res. (1998) 89(3):115-122.
69. ARIËNS RAS, MOIA M, RIVOLTA E; PONTICELLI C, MANNUCCI PM: High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb. Haemost. (1999) 82(3):1020-1023.
70. MATSUDA T, MORISHITA E, JOKAJI H et al.: Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes (1996) 45(Suppl. 3):S109-S110.
71. LEURS PB, VAN OERLE R, WOLFFENBUTTEL BH, HAMULYAK K: Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb. Haemost. (1997) 77(3):472-476.
72. HUVERS FC, DE LEEUW PW, HOUBEN AJ et al.: Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in Type 1 diabetes under near-normoglycemic conditions. Diabetes (1999) 48(6):1300-1307.
73. IVERSEN N, LINDAHL AK, ABILDGAARD U: Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br. J. Haematol. (1998) 102(4):889-895.
74. NOVOTNY WF, PALMIER M, WUN TC, BROZE GJ, JR., MILETICH JP: Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood (1991) 78(2):394-400.
75. ØSTERGAARD P,NORDFANG O, PETERSEN LC, VALENTIN S, KRISTENSEN H: Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Haemostasis (1993) 23(Suppl. 1)107-111.
76. COHEN M, DEMERS C, GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. (1997) 337(7):447-452.
77. SOEJIMA H, OGAWA H, YASUE H et al.: Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb. Res. (1999) 93(1):17-25.
78. GORI AM, PEPE G, ATTANASIO M et al.: Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb. Haemost. (1999) 81(4):589-593.
79. BECKER RC, SPENCER FA, LI Y et al.: Thrombin generation after the abrupt cessation of intravenous unfrac-tionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. J. Am. Coll. Cardiol. (1999) 34(4):1020-1027.
80. LUPU C, POULSEN E, ROQUEFEUIL S et al.: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler. Thromb. Vasc. Biol. (1999) 19(9):2251-2262.
81. HANSEN JB, SANDSET PM, HUSEBY KR et al.: Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br. J. Haematol. (1998) 101(4):638-646.
82. FAREED J, HOPPENSTEADT D, BICK RL: New antithrom-botic drugs: a perspective. Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs (1999) 1(1):40-55.
83. FAREED J, LEWIS BE, CALLAS DD et al.: Antithrombin agents: the new class of anticoagulant and antithrom-botic drugs. Clin. Appl. Thrombosis/Hemostasis (1999) 5(Suppl. 1):S45-S55.
84. WALENGA JM, JESKE W, HOPPENSTEADT D, KAISER B: Factor Xa inhibitors: today and beyond. Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs (1999) 1(1):13-27.
85. BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. (1997) 78(1):471-477.
86. BROZE GJ, JR.: Tissue factor pathway inhibitor gene disruption. Blood Coag. Fibrinol. (1998) 9(Suppl. 1):S89-S92.